Smith & Nephew
As of the edition of 20 October 2026, Smith & Nephew runs 2 drugs, 2 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Collagenase clostridium histolyticum | Ended 1977 (computed from the first US licence) | 0 |
| Becaplermin | Ended 2009 (computed from the first US licence) | 2 |
A route B row is one company at one target.